Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease
Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease
Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience
Objective: To evaluate in a real-world experience high doses of safinamide in patients with fluctuating Parkinson's disease (PD). Background: Standard doses of safinamide (50-100 mg)…Inhaled levodopa (LD) as a treatment for Parkinson’s disease (PD) patients in an emergency setting
Objective: To report on use of CVT-301 (inhaled LD) to treat PD patients with complicated OFF period symptoms who present to the emergency department (ED).…Topographical subtypes of multiple system atrophy: MRI and PET studies
Objective: To investigate the MSA subtypes based on the topography of MSA lesions, employing MRI, PET with [18F]FP-CIT and [18F]FDG PET. Background: Based on the…Camptocormia in patients with multiple system atrophy with different disease durations
Objective: The aims of this study were to explore the prevalence of and factors associated with camptocormia in a cohort of multiple system atrophy (MSA)…FDG-PET degeneration patterns predict amyloid deposition in Corticobasal Syndrome
Objective: To investigate if an individual clinically-focused analysis of brain FDG-PET metabolic patterns and a comprehensive neurological evaluation could distinguish Corticobasal Syndrome (CBS) pathological variants…Potential Diagnosis Biomarks in Serum Biochemical items of Vascular Parkinsonism Patients
Objective: Evaluating the serum biochemical items for diagnosis of vascular parkinsonism. Background: Currently, the most effective diagnostic methods for VP are mainly based on clinical symptoms.…Circadian rhythm alterations in an in vitro cellular model of Spinocerebellar ataxia type 17
Objective: To study in vitro expression of circadian rhythm genes (CLOCK, BMAL) in fibroblasts and neural cells of SCA17 patients. Background: Spinocerebellar Ataxia 17 (SCA17)…Does “5-2-1” identify patients with suspected Advanced Parkinson’s Disease? Evidence of clinical accuracy from G7 countries
Objective: Evaluate the psychometric properties of (i) the “5-2-1” criteria and (ii) consensus-driven clinical indicators of suspected advanced Parkinson’s disease (APD). Background: Recent consensus panel…
- « Previous Page
- 1
- …
- 68
- 69
- 70
- 71
- 72
- …
- 149
- Next Page »